SLK
| Official symbol: | SLK |
| Full name: | STE20 like kinase |
| Location: | 10q24.33-q25.1 |
| Also known as: | KIAA0204, se20-9, STK2 |
| Entrez ID: | 9748 |
| Ensembl ID: | ENSG00000065613 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.61 |
|
|
|
| Recurrently deleted in 3 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Recurrently mutated in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 2 |
|
|
| Fusions detected in 2 cancer type(s) |
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 211.39 (Percentile rank: 82.41%) |
| PubTator score: | 58.28 (Percentile rank: 70.24%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
